Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TACR2 | P21452 | 8/20 | 0.46 |
| ▸ | TACR3 | P29371 | 8/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27563378 | 0.84 | CXCR4 (0.56) | LMNATACR2TACR3OPRM1 | |
| SCHEMBL6629501 | 0.82 | TACR3 (0.43) | DHODHLMNAPDE10ATSHRPOLB | |
| SCHEMBL6851725 | 0.78 | TACR3 (0.59) | TACR2TACR3OPRM1 | |
| SCHEMBL4776786 | 0.77 | DHODH (0.53) | DHODHLMNAPDE10ATSHRPOLB | |
| SCHEMBL5440405 | 0.76 | PDE10A (0.54) | DHODHLMNAPDE10ATSHRPOLB | |
| SCHEMBL6629503 | 0.76 | LMNA (0.52) | LMNATACR2TACR3OPRM1TP53 | |
| SCHEMBL4906728 | 0.76 | PDE10A (0.51) | DHODHLMNAPDE10ATSHRPOLB | |
| SCHEMBL5440506 | 0.75 | DHODH (0.51) | DHODHLMNAPDE10ATSHRPOLB | |
| SCHEMBL6855974 | 0.73 | TACR3 (0.70) | TACR2TACR3OPRM1 | |
| SCHEMBL3587309 | 0.73 | PDE10A (0.57) | DHODHLMNAPDE10ATSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096885-A1 | Quinoline Derivatives as Neurokinin Receptor Antagonists | MERCK SHARP & DOHME LTD. (GB) | 2008-04-24 | — | — | US | claimed |
| CN-1993329-A | Quinoline derivatives as neurokinin receptor antagonists | MERCK SHARP & DOHME (GB) | 2007-07-04 | — | — | CN | claimed |
| EP-1776344-A2 | QUINOLINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2007-04-25 | — | — | EP | claimed |
| WO-2006013393-A2 | QUINOLINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2006-02-09 | — | — | WO | claimed |
| US-20080096885-A1 | Quinoline Derivatives as Neurokinin Receptor Antagonists | MERCK SHARP & DOHME LTD. (GB) | 2008-04-24 | — | — | US | disclosed |
| CN-1993329-A | Quinoline derivatives as neurokinin receptor antagonists | MERCK SHARP & DOHME (GB) | 2007-07-04 | — | — | CN | disclosed |
| EP-1776344-A2 | QUINOLINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2007-04-25 | — | — | EP | disclosed |
| WO-2006013393-A2 | QUINOLINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096885-A1 | Quinoline Derivatives as Neurokinin Receptor Antagonists | TACR3, TACR2, TAC3 | DHODH 3103/4885LMNA 3108/4885PDE10A 2172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.